All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Thanatin-derivative antibiotic
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: CARB-X
Deal Size: $18.4 million Upfront Cash: Undisclosed
Deal Type: Funding October 14, 2020
Details:
Award will support the development of the “thanatin derivatives program” belonging to Polyphor’s novel Outer Membrane Protein Targeting Antibiotic (OMPTA) class of antibiotics to potentially treat life-threatening infections caused by difficult-to-treat Gram-negative bacteria.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MP0420
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
DARPin® candidates targeting SARS-CoV-2 show robust activity in an aggressive viral challenge hamster model, supporting potential efficacy as therapeutic options in patients with late-stage disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Linoleic Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
The team found out that linoleic acid synergizes with currently utilized COVID-19 therapeutics to suppress replication and shut down the virus.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AM-301
Therapeutic Area: Infections and Infectious Diseases Product Name: AM-301
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
AM-301 is a gel which works by forming a protective layer on the nasal mucosa, acting as a physical barrier against airborne pathogens and allergens.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MP0420
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Swiss Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 11, 2020
Details:
Swiss Government will pay a reservation fee for the right to purchase up to 3.2 million doses of anti-COVID-19 DARPin® candidate, MP0420, for both therapeutic and potential prophylactic use.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DARPin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
Details:
Molecular Partners has identified multiple potent monospecific DARPin® proteins which neutralize samples of the SARS-CoV-2 virus.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
